As J&J outlines bullish pipeline goals, neuroscience pipeline takes a starring role

Johnson & Johnson expects neuroscience to play a pivotal role in its newly-announced revenue goals, including two rising stars in adjunctive depression that are slated to rake in at least $1 billion each by 2030.